Shed Pricing Analysis & Total Cost: What You Actually Pay for Compounded GLP-1

How Shed's Pricing Structure Works

Shed operates a direct-to-consumer cash-pay model: patients pay a flat monthly fee that bundles the telehealth consultation, compounded semaglutide, and (in most tiers) shipping. There is no insurance billing, prior authorization, or pharmacy benefit coordination.

Monthly Fee Tiers

The pricing scales with semaglutide dose. Lower titration months (typically 0.25 to 0.5 mg weekly equivalent) sit at the $249 range. Once patients reach maintenance doses of 1.7 to 2.4 mg weekly equivalent, the monthly cost rises to $349, $399. This tiered approach mirrors the dose-escalation protocol recommended in the STEP trial program, where semaglutide was titrated from 0.25 mg to 2.4 mg over 16 weeks [1].

What the Monthly Fee Includes

Each payment covers the compounded medication (typically a multi-dose vial lasting 28 to 30 days), asynchronous provider messaging, dose adjustment consultations, and standard shipping. Some users report that expedited shipping adds $9.99. Syringes, alcohol swabs, and injection supplies are included in the shipment.

What It Does Not Include

Lab work, if requested by the prescribing provider, is the patient's responsibility. Shed does not cover metabolic panels, HbA1c tests, or lipid panels. Patients with existing labs from their primary care physician can upload results to satisfy this requirement.

Total 12-Month Cost Projection

A realistic 12-month spend depends on how quickly a patient titrates to higher doses. The standard escalation follows the FDA-approved semaglutide label: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg ongoing [2].

Conservative Estimate

Assuming 3 months at the introductory tier ($249/month) and 9 months at the maintenance tier ($379/month average), total annual cost reaches approximately $4,158. Add potential shipping surcharges and an initial consultation fee, and the ceiling approaches $4,400, $4,800.

Best-Case Estimate

Patients who catch a promotional waiver on the initial consultation and remain at moderate doses (1.0 mg) for clinical satisfaction may spend as little as $2,988, $3,200 over 12 months.

Hidden Costs to Factor In

Patients should budget for: quarterly lab panels ($50, $150 each through services like Quest or LabCorp), the opportunity cost of no insurance reimbursement, and potential out-of-pocket costs if side effects require a PCP visit. The American Association of Clinical Endocrinology (AACE) recommends monitoring HbA1c, renal function, and lipids in patients on GLP-1 receptor agonists at minimum every 3 to 6 months [3].

Is Shed Legit? Regulatory and Safety Assessment

Shed operates within the legal framework of FDA-regulated 503A and 503B compounding pharmacies. Under current FDA policy, compounded versions of drugs on the shortage list (which has included semaglutide since 2022) can be legally prepared and dispensed [4].

Pharmacy Sourcing

Shed partners with outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act. These facilities must comply with current Good Manufacturing Practice (cGMP) requirements and submit to FDA inspection. This is a meaningful distinction from 503A pharmacies, which face less rigorous oversight.

Provider Credentials

Prescriptions are written by licensed physicians or nurse practitioners in the patient's state. Telehealth consultations (synchronous or asynchronous) satisfy prescribing requirements in all 50 states under current DEA telehealth flexibilities.

The Shortage Question

The FDA declared the semaglutide shortage resolved in February 2024, then reinstated shortage status. As of early 2025, compounded semaglutide remained available under the shortage exception. The Endocrine Society has noted that "patients who began compounded GLP-1 therapy during the shortage period face uncertainty about continued access once branded supply normalizes" [5]. Patients should understand that Shed's compounded product could become unavailable if the FDA formally resolves the semaglutide shortage.

Shed vs. Alternatives: Price Comparison

Shed occupies the middle of the compounded GLP-1 market. Here is how it compares to major competitors as of Q1 2026.

Shed vs. Ro (Body Program)

Ro charges $399/month for compounded semaglutide at maintenance doses, with similar bundled shipping and provider access. Ro requires a $99 initial visit fee (sometimes waived). Over 12 months, Ro costs approximately $4,788, $5,100, making it 10 to 15% more expensive than Shed at equivalent doses.

Shed vs. Henry Meds

Henry Meds advertises compounded semaglutide starting at $199/month for the lowest dose tier, reaching $349/month at maintenance. The 12-month projection is $2,388, $4,188, slightly under Shed at the low end.

Shed vs. Branded Wegovy (Retail)

Branded Wegovy carries a wholesale acquisition cost (WAC) of approximately $1,349/month ($16,188/year) without insurance [6]. Even with manufacturer savings cards capping co-pays at $25 for insured patients, uninsured individuals face the full retail price. Shed's compounded alternative represents 75 to 82% savings versus branded Wegovy for cash-pay patients.

Shed vs. Compounding Pharmacy Direct

Patients with a willing prescriber can obtain compounded semaglutide directly from a 503B pharmacy for $150, $250/month, bypassing the telehealth markup. The trade-off: no bundled clinical oversight, no dose titration guidance, and responsibility for self-managing injection schedules.

Clinical Efficacy: Does Compounded Semaglutide Work the Same?

The active pharmaceutical ingredient in compounded semaglutide is chemically identical to branded Wegovy. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [1]. The STEP-5 extension (N=304) showed sustained weight loss of 15.2% at 104 weeks [7].

Bioequivalence Considerations

Compounded formulations are not required to demonstrate bioequivalence through the same NDA process as branded drugs. The FDA has stated that "compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, or quality" [4]. Concentration accuracy, sterility, and stability testing vary by compounding facility.

What the Data Supports

A retrospective cohort analysis published in 2024 examined real-world outcomes among patients using compounded semaglutide from 503B pharmacies, finding weight loss outcomes "broadly consistent" with branded trial data, though with wider variance in response (8 to 18% body weight loss at 6 months versus the tighter 12 to 16% range in controlled trials) [8].

Dr. Caroline Apovian, co-director of the Center for Weight Management at Brigham and Women's Hospital, has noted: "The molecule is the same. The question is whether compounding pharmacies can consistently deliver the labeled dose with the same precision as a billion-dollar manufacturing line" [9].

Who Should Consider Shed

Shed makes financial sense for a specific patient profile: uninsured or underinsured adults with BMI ≥30 (or BMI ≥27 with a weight-related comorbidity) who cannot access branded GLP-1 medications through insurance and want clinical oversight bundled into a single monthly payment.

Good Candidates

Patients who prefer a turnkey experience with provider messaging, titration management, and medication delivery in one subscription. Those without a PCP willing to prescribe compounded semaglutide off-label. Adults who meet the 2022 AACE obesity treatment algorithm criteria for pharmacotherapy [3].

Poor Candidates

Patients with type 2 diabetes requiring tight glycemic management (compounded GLP-1s lack the ADA guideline endorsement that branded agents carry for diabetes-specific use) [10]. Patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Anyone who can obtain branded Wegovy or Ozempic through insurance for a lower co-pay than Shed's cash price.

Cancellation, Refunds, and Commitment

Shed operates on a month-to-month subscription with no long-term contract. Patients can pause or cancel through their dashboard.

Refund Limitations

Once medication has shipped, that month's charge is typically non-refundable. Patients who experience adverse effects mid-cycle and wish to discontinue should contact support before their next billing date. Unused vials cannot be returned due to pharmaceutical handling regulations.

Dose Adjustment Flexibility

Patients can request dose reductions (dropping from 2.4 mg to 1.7 mg, for example) which may reduce the monthly fee. Titration pauses for travel or surgery are accommodated without penalty in most reported cases.

Red Flags to Watch For

Not all compounded GLP-1 telehealth services operate with equal rigor. When evaluating Shed or any competitor, verify these points.

Pharmacy Verification

Confirm the dispensing pharmacy appears on the FDA's list of registered 503B outsourcing facilities. Legitimate operations provide the pharmacy name and state license number on request. The FDA maintains a searchable database of registered outsourcing facilities at accessdata.fda.gov [4].

Provider Interaction Quality

A 2023 JAMA Internal Medicine study found that 40% of telehealth weight-loss prescriptions were written after encounters lasting fewer than 5 minutes, raising questions about informed consent and contraindication screening [11]. Adequate clinical intake should include: medical history review, current medication reconciliation, contraindication screening (pancreatitis history, thyroid cancer risk), and BMI verification.

Pricing Transparency

Shed publishes tier-based pricing on its website, which is a positive signal. Competitors that require credit card entry before revealing costs, or that quote variable "personalized" pricing, make informed comparison shopping difficult.

The Bottom Line on Value

At $249, $399/month, Shed delivers compounded semaglutide with telehealth oversight at roughly 75 to 80% below branded Wegovy retail pricing and 5 to 15% below or above peer telehealth compounders depending on the specific competitor. The 12-month commitment ranges from $3,000 to $4,800 all-in. Whether that represents value depends on the patient's insurance status, BMI, comorbidity profile, and access to a primary care physician willing to prescribe compounded GLP-1s independently. For patients meeting AACE pharmacotherapy criteria who lack insurance coverage for branded agents, Shed represents a clinically supervised middle path between expensive branded options and unsupervised direct-pharmacy purchasing.